Medical therapy for premature ventricular complex

Outcome of medical treatment for idiopathic premature ventricular complexes – beta-blocker vs Ic antiarrhythmic agent; Randomized controlled trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004120

Enrollment

350

Registered

2019-07-03

Start date

2016-01-06

Completion date

Unknown

Last updated

2019-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients with symptomatic premature ventricular complex are divided into propranolol group (propranolol for 2 months) and propafenone group (propafenone for 2 months).por

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age over 19 years Symptomatic premature ventricular complex >6000 premature ventricular complex in 24-hour Holter

Exclusion criteria

Exclusion criteria: Concomitant structural heart disease left ventricular ejection fraction <50% Use of other antiarrhythmic drugs Significant bradycardia (<40/min)

Design outcomes

Primary

Measure	Time frame
Reduction in premature ventricular complex burden	—

Secondary

Measure	Time frame
Symptom improvement (questionnaire)	—

Countries

Korea, Republic of

Contacts

Public ContactYoung Choi

The Catholic University of Korea, Seoul St. Mary's Hospital

coolnite0@gmail.com+82-2-1588-1511

Outcome results